Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Dowlati, A.
Gray, R.
Johnson, D. H.
Schiller, J. H.
Brahmer, J.
Sandler, A. B.
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Univ Wisconsin, Madison, WI 53706 USA
[5] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：370S / 370S
页数：1
相关论文
共 50 条
  • [21] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A phase I trial of paclitaxel, carboplatin, and gemcitabine in advanced non-small cell lung cancer
    Kelly, K
    Prindiville, S
    Bunn, PA
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 74 - 74
  • [23] Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer
    Soria, Jean-Charles
    Mark, Zsuzsanna
    Zatloukal, Petr
    Szima, Barna
    Albert, Istvan
    Juhasz, Erzsebet
    Pujol, Jean-Louis
    Kozielski, Jerzy
    Baker, Nigel
    Smethurst, Dominic
    Hei, Yong-jiang
    Ashkenazi, Avi
    Stern, Howard
    Amler, Lukas
    Pan, Yang
    Blackhall, Fiona
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4442 - 4451
  • [24] A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Blumenschein, G
    Jotte, R
    von Pawel, J
    Miller, W
    Khuri, F
    Rigas, J
    Mabry, M
    Dziewanowska, Z
    Negro-Vilar, A
    LUNG CANCER, 2005, 49 : S31 - S31
  • [25] Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer
    Nakadate, Megumi
    Yamazaki, Koichi
    Konishi, Jun
    Kinoshita, Ichiro
    Sukoh, Noriaki
    Harada, Masao
    Akie, Kenji
    Ogura, Shigeaki
    Ishida, Takashi
    Munakata, Mitsuru
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    ANTICANCER RESEARCH, 2006, 26 (5B) : 3767 - 3772
  • [26] Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Blumenschein, G. R.
    Kabbinavar, F. F.
    Menon, H.
    Mok, T.
    Stephenson, J.
    Beck, J. T.
    Lakshmaiah, K.
    Kracht, K.
    Sikorski, R. S.
    Schwartzberg, L. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Argiris, A.
    Lee, J.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [29] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    Johnson, DH
    Fehrenbacher, L
    Novotny, WF
    Herbst, RS
    Nemunaitis, JJ
    Jablons, DM
    Langer, CJ
    DeVore, RF
    Gaudreault, J
    Damico, LA
    Holmgren, E
    Kabbinavar, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2184 - 2191
  • [30] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
    Mauer, AM
    Otterson, G
    Rudin, CM
    Villalona, M
    Ansari, RH
    Szeto, L
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
12345